Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Metagenomi

Biotech & Life Sciences · Emeryville, United States · Founded 2017 · IPO 2024 Colt

Discovering the next generation of gene-editing systems for use in treating genetic diseases

Revenue
$25M
Latest reported FY
Featured in $1B+ revenueColt · Power Law growth-stage

Investors

23 investors on Metagenomi's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage
InCube Ventures
Sozo Ventures
Bayer
Leaps by Bayer
Agent Capital
HOF Capital
Humboldt Fund
RA Capital Management
Series B+ 15 investors entered at this stage
Surveyor Capital
Pura Vida Investments
Bristol-Myers Squibb
Frazier Healthcare Partners
Novo Holdings
Deep Track Capital
Marshall Wace
PFM Health Sciences
Farallon Capital Management
Eventide Asset Management
Irving Investors
Moderna Therapeutics
Catalio Capital Management
SymBiosis
Millennium Management

Global footprint

Where Metagenomi has talent and traffic

AI talent share
3.0% of workforce is AI talent
(5 of 164 staff)
Core AI21.22%
Other AI31.83%
Non-AI workforce15996.95%
Workforce by country
🇺🇸 United States · Emeryville HQ
Book a demo for the full country breakdown
Web traffic by country
6.1K monthly visits
across markets
🇺🇸 United States90.2%
🇮🇳 India9.8%
Top 2 markets shown

Market sentiment

What the market is saying about Metagenomi

An AI-synthesized read of the highest-engagement posts about Metagenomi on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Metagenomi on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles